Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 10, 2015, Pages 2862-2869

  Nicolau, David P ^a   Siew, Leonard ^b   Armstrong, Jon ^c   Li, James ^c   Edeki, Timi ^c   Learoyd, Maria ^c   Das, Shampa ^c  

^a HARTFORD HOSPITAL   (United States)

^b IQVIA   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; ANTIINFECTIVE AGENT; AVIBACTAM; AZABICYCLO DERIVATIVE; CEFTAZIDIME;

ABDOMINAL DISCOMFORT; ADULT; ANXIETY; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLOOD SAMPLING; BRONCHOSCOPY; CONCENTRATION AT STEADY-STATE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG ELIMINATION; EPITHELIAL LINING FLUID; FEMALE; HEART PALPITATION; HUMAN; LUNG LAVAGE; MALE; MAXIMUM PLASMA CONCENTRATION; NIGHTMARE; NORMAL HUMAN; OROPHARYNX PAIN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; RHINITIS; SIDE EFFECT; SOMNOLENCE; URINE ODOR; XEROSTOMIA; ADOLESCENT; BODY MASS; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; MUCOSA; PLASMA; RESPIRATORY TRACT MUCOSA; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BODY MASS INDEX; CEFTAZIDIME; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; MUCOUS MEMBRANE; PLASMA; RESPIRATORY MUCOSA; YOUNG ADULT;

EID: 84943771577     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv170     Document Type: Article

References (32)

1. Rotstein C, Evans G, Born A et al. Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can J Infect Dis Med Microbiol 2008; 19: 19-53.
2. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
3. Bassetti M, Taramasso L, Giacobbe DR et al. Management of ventilatorassociated pneumonia: epidemiology, diagnosis and antimicrobial therapy. Expert Rev Anti Infect Ther 2012; 10: 585-96.
4. Vardakas KZ, Tansarli GS, Rafailidis PI et al. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum b-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 2012; 67: 2793-803.
5. Peleg AY, Hooper DC. Hospital-acquired infections due to Gram-negative bacteria. N Engl J Med 2010; 362: 1804-13.
6. Nordmann P, Naas T, Poirel L. Global spread of carbapenemaseproducing Enterobacteriaceae. Emerg Infect Dis 2011; 17: 1791-8.
7. Bush K. Proliferation and significance of clinically relevant b-lactamases. Ann NY Acad Sci 2013; 1277: 84-90.
8. Lagacé-Wiens PR, Tailor F, Simner P et al. Activity of NXL104 in combination with b-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum b-lactamases and class C b-lactamases. Antimicrob Agents Chemother 2011; 55: 2434-7.
9. Livermore DM, Mushtaq S, Warner M et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011; 55: 390-4.
10. Crandon JL, Schuck VJ, Banevicius MA et al. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2012; 56: 6137-46.
11. Housman ST, Crandon JL, Nichols WWet al. Efficacies of ceftazidimeavibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model. Antimicrob Agents Chemother 2014; 58: 1365-71.
12. Sillén H, Mitchell R, Sleigh R et al. Determination of avibactam and ceftazidime in human plasma samples by liquid chromatography and mass spectrometry. Bioanalysis 2015; in press.
13. Furuie H, Saisho Y, Yoshikawa Tet al. Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects. Antimicrob Agents Chemother 2010; 54: 866-70.
14. Rennard SI, Basset G, Lecossier D et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol (1985) 1986; 60: 532-8.
15. MacVane SH, Kuti JL, Nicolau DP. Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2014; 58: 1359-64.
16. Muller AE, Punt N, Mouton JW. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother 2013; 68: 900-6.
17. Berkhout J, Melchers MJ, van Mil AC et al. Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thighand lung-infected mice. Antimicrob Agents Chemother 2015; 59: 2299-304.
18. Berkhout J, Melchers MJ, Van Mil CH et al. Exposure response relationships of ceftazidime and avibactam in a neutropenic thigh model. In: Abstracts of the Fifty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, 2013. Abstract A1023. American Society for Microbiology, Washington, DC, U.S.A.
19. Edeki T, Armstrong J, Li J. Pharmacokinetics of avibactam (AVI) and ceftazidime (CAZ) following separate or combined administration in healthy volunteers. In: Abstracts of the Fifty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, 2013. Abstract A1019. American Society for Microbiology, Washington, DC, U.S.A.
20. Li J, Armstrong J, Edeki T. Pharmacokinetic (PK) drug interaction study of ceftazidime-avibactam (CAZ-AVI) and metronidazole (MTZ) in healthy volunteers. In: Abstracts of the Fifty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, 2013. Abstract A-1020. American Society for Microbiology, Washington, DC, U.S.A.
21. Cazzola M, Gabriella MM, Polverino M et al. Pulmonary penetration of ceftazidime. J Chemother 1995; 7: 50-4.
22. Cars O, Ogren S. Antibiotic tissue concentrations: methodological aspects and interpretation of results. Scand J Infect Dis Suppl 1985; 44: 7-15.
23. Lodise TP, Sorgel F, Melnick D et al. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2011; 55: 1606-10.
24. Boselli E, Breilh D, Rimmele T et al. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 2004; 30: 989-91.
25. GlaxoSmithKline. Ceftazidime 1 g injection SPC. http://www.medicines. org.uk/emc/document.aspx?documentid=19176&docType=SPC.
26. Li J, Zhou D, Al Huniti N et al. Pharmacokinetic/pharmacodynamic target attainment (PTA) and cumulative fractions of response (CFR) for ceftazidime, ceftazidime-avibactam, and meropenem against bacteria isolated from patients in Europe in 2012. In: Abstracts of the Twenty-fourth European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, 2014. Abstract P1747A. European Society of Clinical Microbiology and Infectious Diseases, Basel.
27. Lucasti C, Popescu I, Ramesh MK et al. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J Antimicrob Chemother 2013; 68: 1183-92.
28. Vazquez JA, Gonzalez Patzan LD, Stricklin D et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 2012; 28: 1921-31.
29. Mazuski JE, Gasink L, Armstrong J et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection-results from a Phase III program. In: Abstracts of the Twenty-fifth European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, 2015. Abstract 1731. European Society of Clinical Microbiology and Infectious Diseases, Basel.
30. Honeybourne D. Antibiotic penetration into lung tissues. Thorax 1994; 49: 104-6.
31. Tarral A, Merdjan H. Effect of age and sex on the pharmacokinetics and safety of avibactam in healthy volunteers. Clin Ther 2015; 37: 877-86.
32. Sommers DK, Walters L, VanWyck M et al. Pharmacokinetics of ceftazidime in male and female volunteers. Antimicrob Agents Chemother 1983; 23: 892-6.